Last Price
0.084
Today's Change
0.00 (0.00%)
Day's Change
0.082 - 0.086
Trading Volume
8,648,333
Market Cap
614 Million
Shares Outstanding
7 Billion
Avg Volume
16,521,888
Avg Price (50 Days)
0.10
Avg Price (200 Days)
0.09
PE Ratio
-8.40
EPS
-0.01
Earnings Announcement
28-Feb-2024
Previous Close
0.08
Open
0.08
Day's Range
0.082 - 0.086
Year Range
0.039 - 0.15
Trading Volume
8,648,333
1 Day Change
0.00%
5 Day Change
2.44%
1 Month Change
-23.64%
3 Month Change
-16.00%
6 Month Change
100.00%
Ytd Change
-23.64%
1 Year Change
-35.38%
3 Year Change
-59.02%
5 Year Change
366.67%
10 Year Change
747.63%
Max Change
-99.42%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.